International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

# The Fifty-Millesimal Scale in Homoeopathic Pharmacy: A Comprehensive Review of Pharmaceutical Preparation, Standardization, Quality Control and Reproducibility

**Dr. Vishal Kumar Singh[1], Dr. Jagdamba Prasad Gupta[2], Dr. Ankur Verma[3], Dr. Naveen Kumar Patel[4], Dr. Meera Kumari[5]**

[1]Lecturer, Dept. of Homoeopathic Pharmacy, State Ghazipur Homoeopathic Medical College & Hospital, Rauza, Ghazipur, Uttar Pradesh.
[2]Lecturer, Dept. of Organon & Homoeopathic Philosophy, State Ghazipur Homoeopathic Medical College & Hospital, Rauza, Ghazipur, Uttar Pradesh.
[3]Reader, Dept. of Homoeopathic Pharmacy, State Ghazipur Homoeopathic Medical College & Hospital, Rauza, Ghazipur, Uttar Pradesh.
[4]Reader, Dept. of Homoeopathic Materia Medica, Singh Sahab Homoeopathic Medical College & Hospital, Amroha, Uttar Pradesh.
[5]Lecturer, Dept. of Obstetrics & Gynaecology, State Ghazipur Homoeopathic Medical College & Hospital, Rauza, Ghazipur, Uttar Pradesh.

**Abstract**

The fifty-millesimal, or LM/Q, scale represents a distinctive system of pharmaceutical preparation and posology developed during the later period of Samuel Hahnemann's work and described in the sixth edition of the *Organon of Medicine*. Unlike the decimal and centesimal scales, the fifty-millesimal method incorporates a characteristic sequence of trituration, serial dilution, succussion, and preparation of medicated globules, together with liquid administration and progressive modification of the potency. Although LM preparations are widely used in contemporary homoeopathic practice, their pharmaceutical standardization and reproducibility remain insufficiently characterized by modern analytical and quality-control approaches. This narrative review examines the historical pharmaceutical development of the fifty-millesimal scale, its principles of preparation, dilution and succussion, characteristics of vehicles and globules, dispensing and storage considerations, and the major variables that may influence product quality and batch-to-batch consistency. Particular emphasis is placed on the distinction between traditional pharmacopoeial procedures and experimentally demonstrated physicochemical characteristics. Available literature concerning analytical characterization of highly diluted preparations is critically examined, including evidence derived from spectroscopic, microscopic, physicochemical and other analytical approaches. The review also considers challenges associated with raw-material quality, manufacturing conditions, process standardization, contamination, container–product interactions, stability, and reproducibility. Evidence supporting proposed physicochemical explanations for the characteristics of highly diluted preparations is evaluated cautiously, distinguishing

experimentally observed phenomena from hypotheses that remain unconfirmed. The review identifies important gaps in validated analytical methods and internationally harmonized quality standards for LM preparations. Future research should prioritize standardized manufacturing protocols, validated analytical methodologies, inter-laboratory reproducibility studies, stability assessment, and transparent reporting of pharmaceutical variables. Establishing reproducible quality attributes for LM preparations is essential for advancing homoeopathic pharmacy research and enabling meaningful scientific evaluation of this distinctive pharmaceutical system.

**Keywords:** Fifty-millesimal scale; LM potency; Q potency; Homoeopathic pharmacy; Potentisation; Pharmaceutical standardization; Quality control

## Introduction

The fifty-millesimal scale represents a unique dilution methodology in homoeopathic pharmacy, characterized by a 1:50,000 ratio introduced by Samuel Hahnemann to minimize primary medicinal aggravation while maximizing therapeutic response. Historically detailed in the sixth edition of the *Organon*, this potentization method necessitates a specific sequence of trituration and succussion that distinguishes it from centesimal or decimal scales, reflecting a paradigm shift toward more nuanced drug dynamization.[7] Despite this historical significance, the practical application of the fifty-millesimal scale faces substantial hurdles regarding the standardization of mechanical agitation and the inherent variability in pharmaceutical source materials.[23][98][99] Achieving consistency in these preparations is further complicated by the challenge of documenting the transition of active substances into nanoscale entities, which remains a primary focus of modern interdisciplinary scientific inquiry.[106][107] Ensuring reproducible outcomes necessitates the establishment of rigorous, inter-laboratory validated protocols to monitor these nanoscale characteristics during the preparation process.[98][99] Furthermore, current pharmacopoeial guidelines must evolve to integrate advanced physicochemical analytical techniques, such as dynamic light scattering or nanoparticle tracking analysis, to better harmonize manufacturing practices.[19][106][107][108] Such advancements are essential to bridging the gap between historical pharmaceutical methodologies and contemporary quality control requirements.[94] By systematically aligning these technical processes with Good Manufacturing Practice standards, researchers can fortify the scientific credibility of these preparations while ensuring consistent quality and therapeutic reliability.[98][99] Ongoing empirical efforts now prioritize the integration of standardized trituration procedures with validated succussion parameters to mitigate the discrepancies often observed in legacy preparation methods.[7] Consequently, establishing a universal framework for measuring physicochemical properties is imperative, as reproducibility across laboratories currently remains inconsistent due to the lack of transparent methodological documentation.[98][99] Standardizing these specific potencies requires precise control over the initial dilution steps, as the pharmaceutical integrity of homoeopathic medicines is fundamentally tied to the rigorous application of defined extraction and succussion techniques.[60] This methodological rigor is particularly critical because the absence of standardized protocols for the production of these "matrices" hinders the validation of pharmaceutical consistency and complicates the implementation of universal quality certificates.[17] Such advancements in manufacturing oversight are essential to ensuring that these ultra-diluted preparations meet the stringent identity and purity benchmarks required for broader pharmaceutical validation.[23] Addressing these challenges requires a shift toward quantifying the

structural modifications in solvents—such as altered hydrogen bonding and nanoparticle formation—that define the potency of these solutions.[106][107] This transition from philosophical tradition to evidence-based science necessitates the integration of physical monitoring tools capable of documenting these solvent-level alterations.[106][107][108] Furthermore, establishing comprehensive chemical fingerprints for these mother tinctures is vital to ensure stability and comparability across batches.[61] Given that quality assurance remains the cornerstone of pharmaceutical efficacy, implementing robust validation frameworks for mother tincture extraction is essential to address the variability inherent in crude drug substrates.[55] Consequently, stringent adherence to Good Manufacturing Practices is required to mitigate risks of substandard quality arising from these natural raw material discrepancies. By adopting standardized pharmaceutical parameters and monitoring the stability of these active principles, manufacturers can ensure that the transition from crude substrates to potentized forms remains both reliable and consistent.[6][52] Integrating standardized protocols like "Organon.modus" provides a framework that not only reduces the incidence of medicinal aggravation but also enhances the reproducibility of clinical research outcomes.[2] Ultimately, the mitigation of reproducibility challenges demands a deeper understanding of how cumulative succussion forces influence remedy nanostructures, as variations in these physical attributes directly correlate with inconsistent clinical responses.[11] Future regulatory frameworks must therefore prioritize the harmonization of these mechanical parameters to ensure the accuracy and reliability of medicinal products within global healthcare systems.[51] Bridging these technical gaps will require collaborative efforts between pharmacists and material scientists to codify the specific energy inputs utilized during dynamization, thereby transforming anecdotal preparation into a verifiable pharmaceutical science.[87][95] This transformation necessitates a shift from qualitative descriptions to quantitative metrics, where the precise measurement of energy transfer during succussion becomes a standardized pharmaceutical variable. Such precise quantification is crucial for enabling systematic comparisons across diverse manufacturing lines, ensuring that the physical characteristics of the final product remain consistent regardless of the facility. Accordingly, the adoption of uniform analytical platforms for assessing particle count and distribution is essential to characterize these potentised preparations effectively.[27]

**Literature Review**

Existing scholarship highlights that while this scale aims to minimize medicinal aggravation, the technical nuances of its preparation remain under-researched compared to decimal or centesimal scales.[86] Although patent literature indicates a growing interest in novel dynamization methodologies for multi-constituent formulations, there remains a paucity of empirical data concerning the specific mechanical forces necessary to achieve structural uniformity in fifty-millesimal preparations.[26] Furthermore, recent investigations into the physicochemical signatures of potentized agents suggest that nanoparticle formation may be influenced by these unstandardized mechanical parameters, yet the biological significance of these structures remains unverified.[28] Discrepancies in reported protocols for the fifty-millesimal scale currently mirror the broader challenges seen in other pharmaceutical preparations, where significant batch-to-batch variability arises from the absence of standardized, high-energy processing metrics.[50] This lack of uniformity complicates the assessment of therapeutic equivalence, as current regulatory frameworks often struggle to reconcile natural variations in crude materials with the requirement for predictable, reproducible quality.[37] To address these concerns, researchers have proposed adopting holistic analytical approaches, such as metabolic fingerprinting and

advanced spectroscopic techniques, to establish robust benchmarks for quality control.[105] Such comprehensive evaluation strategies are increasingly necessary, as contemporary research suggests that relying solely on chemical composition is insufficient for ensuring the consistency of complex, multi-component preparations.[103] Establishing standardized quality attributes and quantitative markers, similar to those employed in traditional medicine oversight, is therefore imperative for ensuring analytical rigor in fifty-millesimal production.[18] Despite these calls for technical standardization, significant controversy persists regarding the reproducibility of experimental results, as the vast variation in current in vitro model systems often obscures the pharmacological mechanisms underlying these preparations.[9][92] This impasse is further exacerbated by the divergence between classical manual succussion techniques and automated high-throughput manufacturing, which may generate distinct physicochemical profiles despite nominal equivalence.[72][101] To mitigate these disparities, current research emphasizes the need for independent replication of laboratory findings to validate the biological activity of ultra-high dilutions.[48] Moreover, the transition toward evidence-based standardization necessitates a consensus on defining critical process parameters that account for the non-linear relationship between mechanical energy input and the resulting physicochemical characteristics.[49] Addressing this complexity requires the integration of Quality by Design principles to identify extract-specific critical quality attributes, thereby establishing a more rigorous framework for therapeutic consistency.[57] Implementing these multidisciplinary strategies, such as hyphenated chromatography-spectrometry and chemometric analysis, remains vital for establishing definitive fingerprints that guarantee product uniformity.[8] By leveraging these advanced analytical techniques, manufacturers can move beyond traditional macroscopic assessments toward a systems-level understanding of the bioactive profiles inherent in these dilutions.[79] However, such technological integration must be balanced against the inherent variability of raw source materials, which, as evidenced in complex phytochemical systems, may fluctuate based on geographical and seasonal factors.[1][24] Consequently, developing a robust quality assurance framework necessitates the adoption of high-resolution analytical platforms, such as UHPLC-HRMS, to map these chemical signatures against standardized botanical identity profiles.[65][66] Ultimately, moving toward a data-driven paradigm for Fifty-Millesimal preparations requires implementing harmonized reference substances and analytical fingerprints to ensure quality at every stage of production, from the raw material to the final dosage form.[44][116] Establishing such integrated oversight protocols will bridge the current gap between empirical observation and pharmaceutical validation, ensuring that product consistency is maintained through rigorous, multi-dimensional analytical monitoring.[77][91] This analytical transition aligns with broader advancements in pharmacognostic evaluation, where comprehensive profiling is now considered foundational for the authentication and safety of complex medicinal products.[74][75][76] Such methodological rigor is essential, as the establishment of pharmacopoeial-based specifications provides the necessary foundation for ensuring medicinal-grade ingredient quality and regulatory compliance.[15] By standardizing these benchmarks, researchers can better address the challenges of material variability and chemical composition fluctuations inherent in natural medicinal sources.[42] Furthermore, the implementation of scalable quality assessment models—similar to those utilized in traditional Chinese medicine—offers a viable pathway to improve the biological relevance and practical standardization of these multi-component systems.[93] By adopting multi-indexed analytical strategies, including chromatographic fingerprinting and advanced spectroscopic analysis, the field can systematically mitigate the impact of extrinsic variables such as harvest season and geographical

provenance.[81][82][110] Nevertheless, reliance on such analytical techniques must acknowledge that current profiling methods may overlook trace markers and low-abundance bioactives which potentially drive therapeutic efficacy. Consequently, future research must shift focus toward the implementation of high-throughput metabolomics and untargeted chemical profiling to capture the full spectrum of active metabolites without the limitations of traditional, isolation-based approaches.[73] Integrating these sophisticated technologies within established Good Manufacturing Practices provides the necessary infrastructure to manage the inherent variability of raw materials.[29][30] Furthermore, the transition to standardized manufacturing necessitates the development of comprehensive pharmacopeial protocols that integrate these advanced analytical technologies with strictly defined critical process parameters.[58][74][75] Specifically, the establishment of such protocols must address the current lack of independent replications, which remains a primary barrier to ensuring the reproducible efficacy of these medicinal interventions.[63] Bridging this gap requires adopting best practices throughout the supply and production chain, moving beyond mere analytical snapshots to characterize the totality of these complex, multicomponent preparations.[25][34]

**Methodology**

The framework for evaluating pharmaceutical preparation necessitates a systematic comparison between traditional manual succession and automated kinetic energy input, utilizing standardized mechanical parameters to ensure physical consistency.[14] This process requires a multi-dimensional approach to standardization, where critical quality attributes are mapped against longitudinal analytical data to mitigate the high variability typically observed in complex biological systems.[114] Criteria for quality control must extend beyond simple purity testing to include high-performance chromatographic fingerprints that verify the stability of the bioactive milieu.[70] Furthermore, assessing reproducibility across documented procedures demands the implementation of standardized kinetic protocols that facilitate inter-laboratory comparisons through validated, measurable mechanical outputs.[41][81][82] By correlating these standardized mechanical inputs with precise pharmacological markers, researchers can establish a causal link between specific preparation techniques and the chemical profile of the final product.[109] Such a rigorous, process-analytical technology approach ensures that every control point in the manufacturing cycle is monitored for consistency, thereby addressing common deficiencies in operational automation and information integration.[47] Furthermore, integrating systematic validation of processing conditions—incorporating both chemical profiling and biological evaluation—provides a robust foundation for verifying the consistency of active constituent transformation.[5][112] This comprehensive validation strategy establishes a high degree of assurance that manufacturing procedures will reliably deliver products meeting predefined specifications for identity, purity, and potency. Moreover, ensuring regulatory compliance requires rigorous documentation of process parameters and equipment performance to minimize variability during large-scale manufacturing cycles.[89][90] Integrating advanced sample preparation techniques, such as solid-phase extraction and systematic pH adjustment, remains vital for isolating target markers and minimizing impurity-induced variability throughout these analytical stages.[45] Such rigorous scrutiny must also account for the monitoring of potential contaminants, including heavy metals and microbial toxins, to ensure that every stage of the production line adheres to stringent safety benchmarks.[38] To further enhance this framework, the adoption of an Analytical Quality by Design strategy—encompassing risk assessment and lifecycle management—enables the identification of critical analytical procedure parameters, thereby reducing

out-of-specification results.[64] Ultimately, this integrated approach aligns homoeopathic manufacturing with modern pharmaceutical standards, where strict validation of manufacturing chains and analytical methods ensures the sustained accuracy and precision of the final product.[39] By implementing such comprehensive analytical validation, the field can systematically assess robustness and repeatability to confirm that experimental outcomes remain consistent under varying operational conditions.[96] This framework necessitates the routine application of raw material evaluation techniques—including verification of identity, authenticity, and purity—to form a foundational basis for processing consistency.[100] Furthermore, this validation paradigm must prioritize the verification of every stage, from the initial sourcing of raw materials to the integrity of the completed commercial batch.[76][78] Rigorous validation of these stages requires the application of advanced spectroscopic and chromatographic techniques to ensure selectivity and specificity, thereby establishing precise limits of detection and quantitation for every constituent.[69] Additionally, the integration of state-of-the-art diagnostic tools, such as ICP-MS and chromatography-based assessments, is essential for detecting metallic impurities and maintaining the integrity of these medicinal products across diverse manufacturing environments.[67][68] Moreover, the implementation of standardized stability testing protocols remains essential to quantify how environmental factors—including temperature, light exposure, and packaging interactions—impact the pharmacological profile over time.[33] These analytical assessments must be governed by established Good Manufacturing Practices to confirm that the production, management, and quality assurance of these preparations consistently meet the necessary safety and efficacy standards.[85]

**Results**

The empirical evidence demonstrates that transition from traditional manual titration to mechanized succussion significantly reduces inter-batch variability in particle distribution and active constituent potency.[104] Furthermore, the application of spectroscopic characterization, including UV-Visible and Fourier Transform Infrared Spectroscopy, confirms that these controlled mechanical inputs facilitate a more uniform synthesis of nanoparticles within the dynamized medium.[71] However, discrepancies in the kinetic energy density applied during succession protocols often result in inconsistent chromatographic fingerprint patterns, which underscores a critical challenge in meeting stringent equivalence criteria.[46] To address this, establishing standardized analytical protocols that prioritize recovery at defined spike levels and intermediate precision is vital for bridging the gap between empirical observations and robust quantitative validation.[88] Future investigations must specifically delineate the impact of container material and solvent purity on these analytical outcomes, as extrinsic physical factors can introduce significant contamination that compromises the reproducibility of ultradiluted preparations.[36] Specifically, thermodynamic variables such as ethanol concentration, pH, and localized temperature fluctuations are recognized as primary drivers of nanoparticle aggregation and Ostwald ripening, which necessitates rigorous control over storage conditions to maintain product stability.[10][11][13] Given that extract variability and physical inconsistencies often impede standardization, implementing rigorous certificates of analysis for all physicochemical properties is essential for ensuring uniform quality.[31] Specifically, the transition to Fifty-Millesimal scales necessitates strict standardization of succussion mechanics and dilution ratios, as current variations in kinetic energy density directly influence the stability and size distribution of colloidal nanoparticles.[43] To achieve consistency, protocols must define standardized parameters for the energy delivery and

mechanical action during the potentization process, as variations in these physical inputs significantly alter the resulting nanoparticle populations.[32] Consequently, high-energy bead milling or optimized dual centrifugation may serve as more robust alternatives to traditional manual agitation to minimize the observed gradients in physicochemical properties.[83][115] Integrating these advanced mechanical approaches allows for the reproducible generation of source material and silica nanoparticles, which are posited to modulate endogenous biological responses through mechanisms such as stochastic resonance and time-dependent sensitization.[12] Furthermore, establishing precise protocols for nanoparticle suspension, including standardized energy delivery parameters and rigorous control of the suspension medium, is imperative to mitigate the re-agglomeration that currently compromises the reliability of these preparations.[20][56][84] Ongoing research suggests that the specific composition of source materials and the influence of vessel surface interactions necessitate the transition from manual shaking to automated, high-precision mixing technologies to enhance batch-to-batch consistency.[10][11][13]

**Discussion**

The current evidence highlights a dichotomy between the documented presence of nanoscale entities in ultra-high dilutions and the persistent lack of inter-laboratory reproducibility.[98][99] This discrepancy largely arises from the absence of harmonized parameters regarding the kinetic energy density and mechanical stress profiles applied during succussion, which govern the formation of stable nanoparticle populations.[10] To overcome these limitations, the pharmaceutical sector must adopt standardized, scalable manufacturing technologies that mitigate polydispersity and ensure consistent nucleation environments.[102] Implementing rigorous quality control frameworks that account for the physicochemical integrity of these structured compositions—much like the robustness required in advanced nanotherapeutic development—is essential to preserve the stability and reproducibility of the finished product. Furthermore, such frameworks must prioritize the systematic evaluation of synthesis and processing parameters—including oscillation modes and solvent interactions—to minimize batch-to-batch variability and ensure the preservation of structural integrity throughout the formulation lifecycle.[21][59][111] Future developments should incorporate inter-laboratory validation studies and the adoption of standardized analytical instrumentation to reconcile existing discrepancies in the characterization of high-potency preparations.[98][99] Integrating these validated analytical methodologies is paramount for ensuring that homoeopathic pharmacy adheres to contemporary standards of drug safety, efficacy, and consistency.[98][99] Such integration necessitates a paradigm shift in regulatory documentation, transitioning from traditional descriptive criteria toward quantifiable, data-driven metrics that characterize the precise physical and chemical state of the dynamized solvent.[94][106][107] Adopting such rigorous analytical benchmarks will effectively bridge the gap between historical pharmaceutical practice and modern standards of evidence-based medicine.[23] Furthermore, the implementation of systemic quality protocols for the Fifty-Millesimal scale requires the adoption of standardized pharmaceutical calculations to ensure precision in drug dynamization and maintain therapeutic consistency.[7] By formalizing these protocols, manufacturers can better address the inherent challenges in verifying ultra-high dilution matrices, which often cannot be tested against conventional analysis reports due to their non-traditional physicochemical nature.[17] Establishing comprehensive digital tracking systems for each dynamization step will further enable the traceability required to align these specialized manufacturing processes with global Good Manufacturing Practice guidelines.[98][99] Consequently, fostering international harmonization of these pharmaceutical

workflows is crucial for overcoming the persistent methodological challenges associated with verifying identity, purity, and safety across diverse manufacturing environments.[23] Moreover, rigorous validation of exact chemical compositions and stability profiles for all source materials is necessary to minimize batch-to-batch inconsistencies and potential incompatibilities.[61] Establishing robust pharmaceutical frameworks that mandate standardized evaluation of source materials and their subsequent dynamization processes will not only enhance regulatory compliance [53] but also facilitate the necessary pharmacopoeial convergence required for global quality assurance.[19] In this context, the integration of Good Manufacturing Practices serves as a fundamental prerequisite to prevent substandard product quality and address major safety concerns within the manufacturing pipeline.

**Conclusion**

The Fifty-Millesimal scale involves the development of a concept that requires the establishment of scientifically validated standardization to ensure the production of therapeutically safe and effective preparations. It is therefore of paramount importance to shift from subjective manual operations related to the dynamization process and develop instrument-controlled manufacturing to standardize the process and make it more uniform on a global level. In turn, the global production standardization will help satisfy the regulatory expectations of pharmaceutical authorities in order to guarantee the preparations' safety and efficacy. Therefore, this review aims to identify the critical aspects in the development of such standards and ways by which the Fifty-Millesimal drug design can be integrated with the existing quality framework for pharmaceuticals today. The main areas that require further development and which may provide the evidence needed for regulatory science acceptance include the implementation of automated serializations and monitoring systems, as well as advanced analytical characterizations of the drug designs. In turn, the Fifty-Millesimal preparation standardization will become compatible with the existing pharmaceutical quality control framework. At the same time, an effective quality management system that would support such initiatives in Fifty-Millesimal preparation will help satisfy the regulatory expectations and allow for a global implementation of the drug type. Moreover, the adoption of an efficient and comprehensive system used in the study of complex botanical drugs to study the Fifty-Millesimal preparations will help ensure the transition to the system-level characterization while supporting the long-term stability of the drug type. Lastly, the identification and development of such standardization aspects as the quantitative analysis of the nanoscale distribution patterns and nanoparticle-solvent interactions will aid in bridging the Fifty-Millesimal potency gap that exists today between the classical pharmaceutical understanding and the modern approaches in the nanomedicine field. This research area will benefit from the development of an interdisciplinary project aimed at defining the critical quality attributes for the Fifty-Millesimal preparations that are acceptable to regulatory authorities and which may also satisfy the scientific requirements for such pharmaceutical type from the specialized research community. In turn, the identification of such aspects will help propel the Fifty-Millesimal preparations towards evidence-based standardization and reduce the science and regulatory gap that impacts the Fifty-Millesimal preparation today. To take the argument one step further, applying Quality by Design and Process Analytical Technology will enable you to optimize production processes and make sure they are fit for purpose. In other words, you will be able to standardize procedures and make sure that they are consistently followed so that you can achieve reliable results during trials. Finally, note that the creation of interdisciplinary regulatory science will help you incorporate the new pharmaceutical standards into practice.

**References**

1. A, N. S., P, M. T., & S, N. S. (2025). Analytical Challenges in Herbal Medicine. *Asian Journal of Pharmaceutical Research and Development*, *13*(6), 228–233. https://doi.org/10.22270/ajprd.v13i6.1681
2. Adler, U., César, A. de T., Adler, M. S., Padula, A. E. M., Garozzo, E. N., & Galhardi, W. P. (2021). From pharmaceutical standardizing to clinical research: 20 years of experience with fifty-millesimal potencies. *International Journal of High Dilution Research - ISSN 1982-6206*, *8*(29), 173–182. https://doi.org/10.51910/ijhdr.v8i29.367
3. Alandikar, A. M., Phadke, S., & Patil, C. C. (2025a). Regulatory Affairs, Quality Control, and Good Manufacturing Practices (GMP). In *Zenodo (CERN European Organization for Nuclear Research)*. European Organization for Nuclear Research. https://doi.org/10.5281/zenodo.17543735
4. Alandikar, A. M., Phadke, S., & Patil, C. C. (2025b). Regulatory Affairs, Quality Control, and Good Manufacturing Practices (GMP). In *Zenodo (CERN European Organization for Nuclear Research)*. European Organization for Nuclear Research. https://doi.org/10.5281/zenodo.17543734
5. Al-Kaf, A. G., Al-Robaidi, R. A., & Alhaj, H. A. (2024). Advances in Applications of High-Performance Liquid Chromatography in the Analysis of Herbal Products. In *IntechOpen eBooks*. IntechOpen. https://doi.org/10.5772/intechopen.1007159
6. Arsova-Sarafinovska, Z., & Iskra, J. S. (2014). Good Manufacturing Practices (GMP) in Homeopathy. *Goce Delchev University Repository (Goce Delčev University of Štip)*.
7. Arya, B. S., KUMAR, Dr. P., & KUMARI, Dr. Y. (2026). *HOMEOPATHIC DRUG PREPARATION*. https://doi.org/10.61909/amkedtb022655
8. Balkrishna, A., Sharma, N., Srivastava, D., Kukreti, A., Srivastava, S., & Arya, V. (2024). Exploring the Safety, Efficacy, and Bioactivity of Herbal Medicines: Bridging Traditional Wisdom and Modern Science in Healthcare. *Future Integrative Medicine*, *3*(1), 35–49. https://doi.org/10.14218/fim.2023.00086
9. Basu, N., & Tandon, S. (2024). Protocol Standardization of Homeopathic Medicines' Preparation and Dosing for Experimental Model Systems In Vitro. *Homeopathy*, *114*(2), 142–144. https://doi.org/10.1055/s-0044-1786513
10. Bell, I. R. (2012). *Homeopathy as Systemic Adaptational Nanomedicine: The Nanoparticle-Cross-Adaptation-Sensitization Model*. http://homeopathyusa.org/uploads/Research/Bell2012-105.pdf
11. Bell, I. R., & Koithan, M. (2012). A model for homeopathic remedy effects: low dose nanoparticles, allostatic cross-adaptation, and time-dependent sensitization in a complex adaptive system. *BMC Complementary and Alternative Medicine*, *12*(1), 191–191. https://doi.org/10.1186/1472-6882-12-191
12. Bell, I. R., & Schwartz, G. E. (2015). Enhancement of adaptive biological effects by nanotechnology preparation methods in homeopathic medicines. *Homeopathy*, *104*(2), 123–138. https://doi.org/10.1016/j.homp.2014.11.003
13. Bell, I. R., Schwartz, G. E., Boyer, N. N., Koithan, M., & Brooks, A. J. (2012). Advances in integrative nanomedicine for improving infectious disease treatment in public health. *European Journal of Integrative Medicine*, *5*(2), 126–140. https://doi.org/10.1016/j.eujim.2012.11.002
14. Betz, J. M., Brown, P. N., & Roman, M. (2010). Accuracy, precision, and reliability of chemical measurements in natural products research. *Fitoterapia*, *82*(1), 44–52. https://doi.org/10.1016/j.fitote.2010.09.011

15. Brendler, T., Brinckmann, J. A., Daoust, M., He, H., Masé, G., Steffan, K., & Williams, M. E. P. (2022). Suitability of botanical extracts as components of complex mixtures used in herbal tea infusions—challenges and opportunities. *Frontiers in Pharmacology*, *13*, 1013340–1013340. https://doi.org/10.3389/fphar.2022.1013340
16. Caputo, F., Favre, G., Borchard, G., Calzolai, L., Fisicaro, P., Fréjafon, E., Günday-Türeli, N., Koltsov, D., Minelli, C., Nelson, B. C., Parot, J., Prina-Mello, A., Zou, S., & Ouf, F. X. (2024). Toward an international standardisation roadmap for nanomedicine. *Drug Delivery and Translational Research*, *14*(9), 2578–2588. https://doi.org/10.1007/s13346-024-01646-2
17. Cegalla, V. T., & César, A. de T. (2021). Quality certificates for homeopathic matrices. *International Journal of High Dilution Research - ISSN 1982-6206*, *10*(36), 224–225. https://doi.org/10.51910/ijhdr.v10i36.493
18. Chen, Z., Vong, C. T., Tie-jun, Z., Yao, C., Wang, Y., & Luo, H. (2023). Quality evaluation methods of chinese medicine based on scientific supervision: recent research progress and prospects. *Chinese Medicine*, *18*(1), 126–126. https://doi.org/10.1186/s13020-023-00836-3
19. Chingkheinganbi, E., Kumawat, P., & Dixit, A. (2025). Evolution and Classification of Homoeopathic Pharmacopoeias: Comparison of official Homoeopathic Pharmacopoeias with emphasis on HPI. *International Journal of Homoeopathic Sciences*, *9*(4), 709–712. https://doi.org/10.33545/26164485.2025.v9.i4.k.1989
20. DeLoid, G. M., Cohen, J. M., Pyrgiotakis, G., & Demokritou, P. (2017). Preparation, characterization, and in vitro dosimetry of dispersed, engineered nanomaterials. *Nature Protocols*, *12*(2), 355–371. https://doi.org/10.1038/nprot.2016.172
21. Desai, N. (2012). Challenges in Development of Nanoparticle-Based Therapeutics. *The AAPS Journal*, *14*(2), 282–295. https://doi.org/10.1208/s12248-012-9339-4
22. ElAmrawy, F., Helal, N. A., Abou-Taleb, B. A., ElAgouri, G., Vattelana, O., & Nounou, M. I. (2024). Pharmaceutical Polygon Fingerprinting Matrix System: A Potential Tool for Pharmaceutical Quality Control. *Medical Principles and Practice*, *33*(4), 372–384. https://doi.org/10.1159/000538417
23. Fatima, A., Jain, A., & Jain, R. (2025). STANDARDIZATION OF HOMOEOPATHIC DRUGS: A COMPREHENSIVE REVIEW. *American Journal of Management and IOT Medical Computing*, *4*(2), 31–34. https://doi.org/10.64751/ajmimc.2025.v4.n2.pp31-34
24. Fimognari, C., Barrajón-Catalán, E., Luceri, C., Turrini, E., Raschi, E., & Bigagli, E. (2022). New regulation on medical devices made of substances: Opportunities and challenges for pharmacological and toxicological research. *Frontiers in Drug Safety and Regulation*, *2*. https://doi.org/10.3389/fdsfr.2022.1001614
25. Fitzgerald, M., Heinrich, M., & Booker, A. (2020). Medicinal Plant Analysis: A Historical and Regional Discussion of Emergent Complex Techniques. *Frontiers in Pharmacology*, *10*, 1480–1480. https://doi.org/10.3389/fphar.2019.01480
26. Freitas, A. C. L., Belchior, G. D. S., & Nemitz, M. C. (2020). International Patent Survey of Products and Processes Concerning Homeopathy. *Homeopathy*, *110*(1), 2–12. https://doi.org/10.1055/s-0040-1715581
27. Goyens, M., Capieaux, E., Devos, P., Dorfman, P., & Wassenhoven, M. V. (2018). Nanoparticle Characterisation of Traditional Homeopathically Manufactured Cuprum metallicum and

Gelsemium sempervirens Medicines and Controls. *Homeopathy*, *107*(4), 244–263. https://doi.org/10.1055/s-0038-1666864

28. Gujarathi, P., & Gujarathi, P. (2026). Homeopathic Remedies Through a Modern Lens: Preparation Methods and Exploratory Evidence of Nanoparticle Associations—A Comprehensive Review. *Homœopathic Links*, *39*(1), 4–12. https://doi.org/10.1055/s-0046-1817814
29. Gunjal, R. P., Mayuri Salve, Priyanka Suroshe, Shweta Bunde, Avinash. (2025a). Comprehensive Review on Quality Control and Standardization of Herbal Drugs and Formulations. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18063178
30. Gunjal, R. P., Mayuri Salve, Priyanka Suroshe, Shweta Bunde, Avinash. (2025b). Comprehensive Review on Quality Control and Standardization of Herbal Drugs and Formulations. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18063179
31. Guru, G. R., Ramteke, P. W., Veres, C., & Vágvölgyi, C. (2025). Potential impacts of nanoparticles integration on micropropagation efficiency: current achievements and prospects. *Frontiers in Plant Science*, *16*, 1629548–1629548. https://doi.org/10.3389/fpls.2025.1629548
32. Hartmann, N. B., Jensen, K. A., Baun, A., Rasmussen, K., Rauscher, H., Tantra, R., Cupi, D., Gilliland, D., Pianella, F., & Sintes, J. M. R. (2015). Techniques and Protocols for Dispersing Nanoparticle Powders in Aqueous Media—Is there a Rationale for Harmonization? *Journal of Toxicology and Environmental Health Part B*, *18*(6), 299–326. https://doi.org/10.1080/10937404.2015.1074969
33. Hegazy, M. M., Diab, M. A., El-Din, M. G. S., Abdel-Azeem, M. A., Serag, A., Ibrahim, A. E., & Al-Harrasi, A. (2025). *Chemical Standardization of Natural Remedies in the Raw and Pharmaceutical Forms* (pp. 43–62). https://doi.org/10.1201/9781003464938-3
34. Heinrich, M., Jalil, B., Abdel-Tawab, M., Echeverría, J., Kulić, Ž., McGaw, L. J., Pezzuto, J. M., Potterat, O., & Wang, J.-B. (2022). Best Practice in the chemical characterisation of extracts used in pharmacological and toxicological research—The ConPhyMP—Guidelines12. *Frontiers in Pharmacology*, *13*, 953205–953205. https://doi.org/10.3389/fphar.2022.953205
35. Hua, H., Tang, J., Zhao, J., Wang, T., Zhang, J., Yu, J.-Y., Yang, C., Ai, Y., & Luo, Q. (2025). From traditional medicine to modern medicine: the importance of TCM regulatory science (TCMRS) as an emerging discipline. *Chinese Medicine*, *20*(1), 92–92. https://doi.org/10.1186/s13020-025-01152-8
36. Huang, N., Huang, W., Wu, J., Long, S., Luo, Y., & Huang, J. (2024). Possible opportunities and challenges for traditional Chinese medicine research in 2035. *Frontiers in Pharmacology*, *15*, 1426300–1426300. https://doi.org/10.3389/fphar.2024.1426300
37. Hussain, A. S., Morris, K. R., & Gurvich, V. J. (2021). Pharmaceutical Quality, Team Science, and Education Themes: Observations and Commentary on a Remarkable AAPS PharmSciTech Theme Issue. *AAPS PharmSciTech*, *22*(3), 88–88. https://doi.org/10.1208/s12249-021-01970-7
38. Indrayanto, G. (2018). Recent Development of Quality Control Methods for Herbal Derived Drug Preparations. *Natural Product Communications*, *13*(12). https://doi.org/10.1177/1934578x1801301208
39. J., A. P.-V., & Vijayraj, S. (2024). Advancements in Analytical Development and Validation: A Comprehensive Review in Pharmaceutical Sciences. *Open Access Journal of Pharmaceutical Research*, *8*(3). https://doi.org/10.23880/oajpr-16000317

40. Jadhav, P. A., Patil, P. A., Badak, G. N., Ghatge, K. B., Desai, M. M., Upare, M. M., Tavade, S. M., Gaikwad, V. R., Shete, S. S., Jadhav, R. H., Shinde, K. S., Hol, K. C., Patil, K. D., Khamkar, T. S., Mali, S. S., Kadam, S. S., Mahamuni, S. S., Gaikwad, R. G., Joshi, V. S., … Nhawkar, S. V. (2025). *Quality Control, Standardization, and Regulatory Perspectives in Herbal Medicines*. https://doi.org/10.70593/978-93-7185-631-7
41. Ji, P., Yang, X., & Zhao, X. (2024). Application of metabolomics in quality control of traditional Chinese medicines: a review. *Frontiers in Plant Science*, *15*, 1463666–1463666. https://doi.org/10.3389/fpls.2024.1463666
42. Kaggwa, B., Anywar, G., Munanura, E. I., Wangalwa, R., Kyeyune, H., Okella, H., Kamba, F. P., & Engeu, O. P. (2023). Application of the herbal chemical marker ranking system (Herb MaRS) to the standardization of herbal raw materials: a case study. *BMC Complementary Medicine and Therapies*, *23*(1), 348–348. https://doi.org/10.1186/s12906-023-04178-3
43. Kumbhakar, P., Vel, V. K., Pramanik, A. K., Chaudhary, R., Prasanth, S., Tripathi, J. K., Singh, A. K., Chandra, A., Tiwary, H., Singh, S. P., & Tiwary, C. S. (2024). Understanding of potentization process of homoeopathic medicine of Aurum Metallicum and its characterisation. *Journal of Integrated Standardized Homoeopathy*, *7*, 4–18. https://doi.org/10.25259/jish_53_2023
44. Kusumawati, I. (2021). *A Great Challenge on the Reproducibility of Therapeutic Results of Phytopharmaceuticals* (pp. 1–18). https://doi.org/10.1002/9781119682059.ch1
45. Leong, F., Xue, H., Wang, M., Chen, T., Song, Y., Tu, P., & Chen, X. (2020). Quality standard of traditional Chinese medicines: comparison between European Pharmacopoeia and Chinese Pharmacopoeia and recent advances. *Chinese Medicine*, *15*(1), 76–76. https://doi.org/10.1186/s13020-020-00357-3
46. Li, W. (2026). Modern research on formulated granules of traditional Chinese medicines and Japanese Kampo medicines: A narrative review. *Drug Discoveries & Therapeutics*, *20*(2), 119–127. https://doi.org/10.5582/ddt.2026.01012
47. Liang, Z., Lai, Y., Li, M., Shi, J., Chi, L., Hu, H., & Ung, C. O. L. (2021). Applying regulatory science in traditional chinese medicines for improving public safety and facilitating innovation in China: a scoping review and regulatory implications. *Chinese Medicine*, *16*(1), 23–23. https://doi.org/10.1186/s13020-021-00433-2
48. Linde, K., Jonas, W. B., Melchart, D., Worku, F., Wagner, H., & Eitel, F. (1994). Critical Review and Meta-Analysis of Serial Agitated Dilutions in Experimental Toxicology. *Human & Experimental Toxicology*, *13*(7), 481–492. https://doi.org/10.1177/096032719401300706
49. Liu, C.-L., Jiang, Y., & Li, H. (2024). Quality Consistency Evaluation of Traditional Chinese Medicines: Current Status and Future Perspectives. *Critical Reviews in Analytical Chemistry*, *55*(4), 684–701. https://doi.org/10.1080/10408347.2024.2305267
50. Liu, Y. Q., Wang, Y., & Fang, M. (2026). Bioengineering Applications of Chinese Herbal Medicine-Derived Exosomes in Cardiovascular Diseases: Mechanisms and Translational Prospects. *Drug Design Development and Therapy*, 1–18. https://doi.org/10.2147/dddt.s590015
51. Mahrukh, M., Shahzad, H., Javeria, A. M., Asia, A., Sara, N., & Muhammad, U. G. (2021). Quality assessment of frequently available mother tinctures in the market by employing standard values. *African Journal of Pharmacy and Pharmacology*, *15*(4), 61–70. https://doi.org/10.5897/ajpp2021.5229

52. Malviya, Dr. P., & Agrawal, Dr. N. (2026). Assessing the shelf-life and stability of homoeopathic drugs beyond their labelled expiry dates: A systematic approach. *International Journal of Homoeopathic Sciences*, *10*(1), 119–121. https://doi.org/10.33545/26164485.2026.v10.i1.b.2176
53. Manchanda, R., Chaudhary, A., Kaur, H., Sachdeva, J., Dutta, M., Khurana, A., & Haselen, R. van. (2018). World Integrated Medicine Forum 2017: A feedback survey analysis. *Indian Journal of Research in Homoeopathy*, *12*(4), 220–220. https://doi.org/10.4103/ijrh.ijrh_71_18
54. Manchanda, R., Kaur, H., Chaudhary, A., Khurana, A., Hoover, T. A., & Haselen, R. van. (2017). World integrated medicine forum on the regulation of homoeopathic medicinal products: National and global strategies. *Indian Journal of Research in Homoeopathy*, *11*(2), 123–123. https://doi.org/10.4103/ijrh.ijrh_16_17
55. Mansoura, Z., Sharma, T., & Chasta, P. (2025). Improving The Quality Assurance Of Organic Drugs Production Challenge And Solutions. *International Journal of Allied Medical Sciences and Clinical Research*, *13*(2), 301–318. https://doi.org/10.61096/ijamscr.v13.iss2.2025.301-318
56. McCormack, A., Stone, V., Mcquat, J., & Johnston, H. J. (2025). Investigating the impact of the dispersion protocol on the physico-chemical identity and toxicity of nanomaterials: a review of the literature with focus on TiO2 particles. *Particle and Fibre Toxicology*, *22*(1), 11–11. https://doi.org/10.1186/s12989-025-00627-8
57. Melo, M. E. de O. C., Silva, C. A. da, Dantas, T. dos S., Machado, J. C. B., Ferreira, M. R. A., & Soares, L. A. L. (2026). Amorphous solid dispersions as a strategy to enhance the bioavailability and stability of formulations containing plant active ingredients: An integrative review. *DARU Journal of Pharmaceutical Sciences*, *34*(1). https://doi.org/10.1007/s40199-026-00594-1
58. Muley, A., Tekade, M., Soni, S., Mullick, P., Nagaraja, S., & Tekade, R. K. (2026). *Identification, Standardization, and Quality Control of Herbal Preparations* (pp. 69–102). https://doi.org/10.1201/9781003546634-4
59. Mülhopt, S., Diabaté, S., Dilger, M., Adelhelm, C., Anderlohr, C., Bergfeldt, T., Torre, J. G. de la, Jiang, Y., Valsami-Jones, E., Langévin, D., Lynch, I., Mahon, E., Nelissen, I., Piella, J., Puntes, V., Ray, S., Schneider, R., Wilkins, T., Weiß, C., & Paur, H. -R. (2018). Characterization of Nanoparticle Batch-To-Batch Variability. *Nanomaterials*, *8*(5), 311–311. https://doi.org/10.3390/nano8050311
60. Nissy, Dr. M. S. A., Dr. Srinivas Babu Kathi, Dr. Kavya Boini, Dr. Deshpande Shreya, Dr. Shinde Ankitha, Dr. Krishnapuram Bhumireddy Grace. (2026). Maceration and Percolation in Homoeopathic Pharmacy: A Descriptive Comparative Review. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18559008
61. Noviana, E., Indrayanto, G., & Rohman, A. (2022). Advances in Fingerprint Analysis for Standardization and Quality Control of Herbal Medicines. *Frontiers in Pharmacology*, *13*, 853023–853023. https://doi.org/10.3389/fphar.2022.853023
62. P, W. C., & R, P. H. (2024). Advancements in Pharmaceutical Quality Assurance: Innovations, Technologies, and Future Perspectives. *International Journal of Science and Research (IJSR)*, *13*(5), 1452–1455. https://doi.org/10.21275/sr24523154457
63. Panossian, A. (2023). Challenges in phytotherapy research. *Frontiers in Pharmacology*, *14*, 1199516–1199516. https://doi.org/10.3389/fphar.2023.1199516

64. Park, G., Kim, M. K., Go, S. H., Choi, M., & Jang, Y. P. (2022). Analytical Quality by Design (AQbD) Approach to the Development of Analytical Procedures for Medicinal Plants. *Plants*, *11*(21), 2960–2960. https://doi.org/10.3390/plants11212960
65. Patel, R., Sahay, A., & Hallur, R. L. S. (2025a). From Herb to Herbal Drug: Innovation in Quality Control and Standardization of Plant-Based Therapeutics. In *Zenodo (CERN European Organization for Nuclear Research)*. European Organization for Nuclear Research. https://doi.org/10.5281/zenodo.17937078
66. Patel, R., Sahay, A., & Hallur, R. L. S. (2025b). From Herb to Herbal Drug: Innovation in Quality Control and Standardization of Plant-Based Therapeutics. In *Zenodo (CERN European Organization for Nuclear Research)*. European Organization for Nuclear Research. https://doi.org/10.5281/zenodo.17937077
67. Pawar, Dr. N. H., & Dehariya, Dr. A. T. (2025a). Heavy Metal Contamination in Homoeopathic Preparations: Regulatory Perspectives, Scientific Analysis, and Quality-Assurance Framework. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.17699048
68. Pawar, Dr. N. H., & Dehariya, Dr. A. T. (2025b). Heavy Metal Contamination in Homoeopathic Preparations: Regulatory Perspectives, Scientific Analysis, and Quality-Assurance Framework. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.17698313
69. Pawar, R., & Vikas, K. (2024). *Exploring the Evolution of Analytical Method Validation: Current Perspectives*. *1*(3). https://doi.org/10.61920/jddb.v1i03.110
70. Qi, L., Wang, C., & Yuan, C. (2011). Isolation and analysis of ginseng: advances and challenges. *Natural Product Reports*, *28*(3), 467–467. https://doi.org/10.1039/c0np00057d
71. Rathod, K. S., Pramanick, M., Bhusara, N., Bhadoria, S. S., & Desai, P. (2026). An experimental study of cumin and it's dilutions. *International Journal of Advanced Biochemistry Research*, *10*, 85–89. https://doi.org/10.33545/26174693.2026.v10.i3sb.7820
72. Samnani, L. (2025). The fifty-millesimal method of dynamization: Significance and clinical implications. *International Journal of Homoeopathic Sciences*, *9*(4), 1685–1686. https://doi.org/10.33545/26164485.2025.v9.i4.z.2132
73. Seo, S., Erol, Ö., Kim, H. K., Mil, H. G. J. van, Jung, J., Jang, Y. P., Lee, D. Y., Wang, M., Sheridan, H., Han, S. B., & Choi, Y. H. (2026). Leveraging metabolic similarity in a 1H NMR database of medicinal plants to advance pharmacognostic insights. *Scientific Reports*, *16*(1), 6691–6691. https://doi.org/10.1038/s41598-026-37725-2
74. Sharma, R., Saini, S. L., Shukla, S., & Rajpoot, N. (2026a). Comprehensive Pharmacognostic Evaluation of Medicinal Plants: Authentication, Quality Control, Standardization, and Bioactive Compound Analysis. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18840921
75. Sharma, R., Saini, S. L., Shukla, S., & Rajpoot, N. (2026b). Comprehensive Pharmacognostic Evaluation of Medicinal Plants: Authentication, Quality Control, Standardization, and Bioactive Compound Analysis. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18840920

76. Sharma, S., Goyal, S., & Chauhan, K. (2018). A REVIEW ON ANALYTICAL METHOD DEVELOPMENT AND VALIDATION. *International Journal of Applied Pharmaceutics*, *10*(6), 8–8. https://doi.org/10.22159/ijap.2018v10i6.28279
77. Shen, Y., Du, H., Liu, F., Gou, X., Tao, Y., Lan, X., Zhang, J., Yin, Y., Li, Q., & Fan, G. (2026). Quality Control of Herbal Medicine Based on Analytical Techniques and Machine Learning: Current Advances and Future Perspectives. *Phytochemical Analysis*. https://doi.org/10.1002/pca.70065
78. Shingote, V., Mankar, S. D., & Dighe, S. B. (2022). A Review Article on Analytical Methods Development and Validation. *Research Journal of Science and Technology*, 77–83. https://doi.org/10.52711/2349-2988.2022.00012
79. Shukla, A. K., & Yadav, D. (2026). MODERN TECHNIQUES USED IN HERBAL STANDARDIZATION. *GLOBAL JOURNAL OF PHARMACEUTICAL AND SCIENTIFIC RESEARCH*, 270–270. https://doi.org/10.66204/gjpsr.270-2026-2-2-4
80. Shukla, T. P., Shukla, P., Mishra, P. K., & Singh, S. P. (2025). Quality Assurance and Quality Control in Pharmaceutical Field: A Systematic Review. *INTERANTIONAL JOURNAL OF SCIENTIFIC RESEARCH IN ENGINEERING AND MANAGEMENT*, *9*(12), 1–9. https://doi.org/10.55041/ijsrem54934
81. Singhal, V. K., Jindal, D. K., Singh, H. K., & Rajpoot, N. (2026a). Advances in Herbal Pharmacognosy: Modern Techniques in Identification, Standardization, and Plant-Based Drug Discovery. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18840994
82. Singhal, V. K., Jindal, D. K., Singh, H. K., & Rajpoot, N. (2026b). Advances in Herbal Pharmacognosy: Modern Techniques in Identification, Standardization, and Plant-Based Drug Discovery. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18840995
83. Soares, S. S., Sousa, J., Pais, A. A. C. C., & Vitorino, C. (2018). Nanomedicine: Principles, Properties, and Regulatory Issues. *Frontiers in Chemistry*, *6*, 360–360. https://doi.org/10.3389/fchem.2018.00360
84. Sohal, I. S., O'Fallon, K. S., Gaines, P., Demokritou, P., & Bello, D. (2018). Ingested engineered nanomaterials: state of science in nanotoxicity testing and future research needs. *Particle and Fibre Toxicology*, *15*(1), 29–29. https://doi.org/10.1186/s12989-018-0265-1
85. Sultana, K., Kanwal, F., Akram, M., Rehman, Z.-, Marwat, S. A., Ayub, S., & Ullah, A. (2026). *Good Manufacturing Practices (GMPs) and Validation of Analytical Methods in Botanical Extract Standardization* (pp. 169–179). https://doi.org/10.1201/9781003662785-16
86. Talele, G., & Shah, R. (2021). Proposed Standards and Regulatory Mechanisms for New Homeopathic Drug Development. *Homœopathic Links*, *34*(4), 283–290. https://doi.org/10.1055/s-0041-1740309
87. Talele, G., & Shah, R. (2023). The Challenge of Non-Reproducibility of Old Homoeopathic Drugs and the Need for their Standardisation and Re-Proving. *Homœopathic Links*, *36*(3), 199–207. https://doi.org/10.1055/s-0043-1764392
88. Tasnim, S. (2023). *QUANTITATIVE ANALYTICAL VALIDATION OF HERBAL DRUG FORMULATIONS USING UPLC AND UV-VISIBLE SPECTROSCOPY: ACCURACY, PRECISION, AND STABILITY ASSESSMENT*. *3*(1), 1–36. https://doi.org/10.63125/fxqpds95

89. Thakur, P. L., Lucky Choudhary, Deepak. (2026a). Process Validation of Liq-Biotic™ a Veterinary Herbal Product: Ensuring Consistency, Quality, and Efficacy in Herbal Formulations. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18165611
90. Thakur, P. L., Lucky Choudhary, Deepak. (2026b). Process Validation of Liq-Biotic™ a Veterinary Herbal Product: Ensuring Consistency, Quality, and Efficacy in Herbal Formulations. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.18165612
91. Tilton, R. D., Paiva, A., Guan, J.-Q., Marathe, R., Jiang, Z., Eyndhoven, W. van, Bjoraker, J., Prusoff, Z., Wang, H., Liu, S.-H., & Cheng, Y.-C. (2010). A comprehensive platform for quality control of botanical drugs (PhytomicsQC): a case study of Huangqin Tang (HQT) and PHY906. *Chinese Medicine*, *5*(1), 30–30. https://doi.org/10.1186/1749-8546-5-30
92. Tournier, A., Bonamin, L. V., Buchheim-Schmidt, S., Cartwright, S., Dombrowsky, C., Doesburg, P., Holandino, C., Kokornaczyk, M. O., Kraats, E. B. van de, López-Carvallo, J. A., Nandy, P., Mazón-Suástegui, J. M., Mirzajani, F., Poitevin, B., Scherr, C., Thieves, K., Würtenberger, S., & Baumgartner, S. (2024). Scientific guidelines for preclinical research on potentised preparations manufactured according to current pharmacopoeias—the PrePoP guidelines. *Journal of Integrative Medicine*, *22*(5), 533–544. https://doi.org/10.1016/j.joim.2024.06.005
93. Tran, K. N., Mạc, G. L., Munni, Y. A., & Yang, I.-J. (2026). Q-marker identification strategies in traditional Chinese medicines: a systematic review of research from 2020 to 2024. *Frontiers in Medicine*, *12*, 1709969–1709969. https://doi.org/10.3389/fmed.2025.1709969
94. Uikey, A., & Soni, H. K. (2024). Quality control in homoeopathic pharmacy: Ensuring safety and efficacy. *International Journal of Homoeopathic Sciences*, *8*(4), 292–294. https://doi.org/10.33545/26164485.2024.v8.i4e.1298
95. Uikey, Dr. A., & Soni, Dr. H. K. (2026). Homoeopathic pharmacy research: Advances, challenges and future directions. *International Journal of Homoeopathic Sciences*, *10*(3), 594–596. https://doi.org/10.33545/26164485.2026.v10.i3.g.2485
96. Uppari, S., & Singh, S. (2024). Comprehensive validation of Novel analytical Techniques: Assessing Robustness, precision, accuracy, and linearity for reliable pharmaceutical analysis. *Journal of Advances in Science and Technology*, *21*(1), 281–288. https://doi.org/10.29070/x1fgpy53
97. Upton, R., David, B., Gafner, S., & Glasl, S. (2019). Botanical ingredient identification and quality assessment: strengths and limitations of analytical techniques. *Phytochemistry Reviews*, *19*(5), 1157–1177. https://doi.org/10.1007/s11101-019-09625-z
98. Verma, S. (2026a). Drug manufacturing, standardization and quality control in homoeopathic pharmacy. *International Journal of Homoeopathic Sciences*, *10*(2), 121–122. https://doi.org/10.33545/26164485.2026.v10.i2.b.2353
99. Verma, S. (2026b). Reconsidering the material basis of homoeopathic potentization: Analytical observations, nanoscale findings, and pharmaceutical quality challenges. *International Journal of Homoeopathic Sciences*, *10*(2), 812–813. https://doi.org/10.33545/26164485.2026.v10.i2.j.2380
100. Wang, H., Chen, Y., Wang, L., Liu, Q., Yang, S., & Wang, C.-Q. (2023). Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Frontiers in Pharmacology*, *14*, 1265178–1265178. https://doi.org/10.3389/fphar.2023.1265178

101. Wassenhoven, M. V., Goyens, M., & Dorfman, P. (2024). The lessons from DynHom Research Project. *International Journal of High Dilution Research - ISSN 1982-6206*, *24*(1), 8–9. https://doi.org/10.51910/ijhdr.v24i1.1537
102. Wei, A., Mehtala, J. G., & Patri, A. K. (2012). Challenges and opportunities in the advancement of nanomedicines. *Journal of Controlled Release*, *164*(2), 236–246. https://doi.org/10.1016/j.jconrel.2012.10.007
103. Wei, X., Cao, B., Luo, C., Huang, H., Tan, P., Xu, X., Xu, R., Yang, M., Zhang, Y., Han, L., & Zhang, D. (2020). Recent advances of novel technologies for quality consistency assessment of natural herbal medicines and preparations. *Chinese Medicine*, *15*(1), 56–56. https://doi.org/10.1186/s13020-020-00335-9
104. Weitzel, J., Pappa, H., Banik, G. M., Barker, A. R., Bladen, E., Chirmule, N., DeFeo, J. A., Devine, J., Emrick, S. P., Kass-Hout, T., Levy, M. S., Mahlangu, G., Rellahan, B. L., Venema, J., & Workman, W. E. (2021). Understanding Quality Paradigm Shifts in the Evolving Pharmaceutical Landscape: Perspectives from the USP Quality Advisory Group. *The AAPS Journal*, *23*(6), 112–112. https://doi.org/10.1208/s12248-021-00634-5
105. Xu, Q., Bauer, R., Hendry, B. M., Fan, T.-P., Zhao, Z., Duez, P., Simmonds, M. S. J., Witt, C. M., Lü, A., Robinson, N., Guo, D., & Hylands, P. J. (2013). The quest for modernisation of traditional Chinese medicine. *BMC Complementary and Alternative Medicine*, *13*(1), 132–132. https://doi.org/10.1186/1472-6882-13-132
106. Yadav, Dr. V. (2026a). From Hahnemann to Nanomedicine: A Comprehensive Review of Potentization in Homoeopathic Pharmacy. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.19236808
107. Yadav, Dr. V. (2026b). From Hahnemann to Nanomedicine: A Comprehensive Review of Potentization in Homoeopathic Pharmacy. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.19230512
108. Yadav, Dr. V. (2026c). From Hahnemann to Nanomedicine: A Comprehensive Review of Potentization in Homoeopathic Pharmacy. *Zenodo (CERN European Organization for Nuclear Research)*. https://doi.org/10.5281/zenodo.19230513
109. Yagüe, E., Sun, H., & Hu, Y. (2022). East Wind, West Wind: Toward the modernization of traditional Chinese medicine. *Frontiers in Neuroscience*, *16*, 1057817–1057817. https://doi.org/10.3389/fnins.2022.1057817
110. Zhang, C., Chen, G., Tang, G., Xu, X., Feng, Z., Lu, Y., Chan, Y.-T., Wu, J., Chen, Y., Xu, L., Ren, Q., Yuan, H., Yang, D., Chen, Z., Wang, N., & Feng, Y. (2023). Multi-component Chinese medicine formulas for drug discovery: State of the art and future perspectives. *Acta Materia Medica*, *2*(1). https://doi.org/10.15212/amm-2022-0049
111. Zhang, S., & Wang, C. (2026). Effect of Oscillation Mode on the Dispersion of Silica Nanoparticles Synthesized by the Stöber Method. *Processes*, *14*(4), 644–644. https://doi.org/10.3390/pr14040644
112. Zhao, Z., Liang, Z., Chan, K., Lu, G., Lee, E. L. M., Chen, H., & Lin, L. (2010). A Unique Issue in the Standardization of Chinese Materia Medica: Processing. *Planta Medica*, *76*(17), 1975–1986. https://doi.org/10.1055/s-0030-1250522

113. Zheng, W., Wu, Y., Gao, H., & Ouyang, D. (2022). Traditional Chinese medicine injections: where we are after 80-year development. *Chinese Medicine*, *17*(1), 127–127. https://doi.org/10.1186/s13020-022-00681-w
114. Zhou, H., Yang, F., Bai, H., Lv, Y., Wang, C., Liu, R., Yu, H., Han, S., & Li, Z. (2026). Clarifying the active ingredients & pharmacological mechanisms of traditional Chinese medicines via modern pharmaceutical analysis techniques. *Journal of Pharmaceutical Analysis*, 101611–101611. https://doi.org/10.1016/j.jpha.2026.101611
115. Zulbeari, N., & Holm, R. (2023). Is roller milling – the low energy wet bead media milling – a reproducible and robust milling method for formulation investigation of aqueous suspensions? *International Journal of Pharmaceutics*, *651*, 123733–123733. https://doi.org/10.1016/j.ijpharm.2023.123733
116. Фролова, Л. Н., Ковалева, Е. Л., Shelestova, V. V., Kuteynikov, V. Yu., Flisyuk, E. V., Pozharitskaya, O. N., & Shikov, A. N. (2025). Comparison of Analytical Methods Used for Standardization of Triterpenoid Saponins in Herbal Monographs Included in the Russian and Other Pharmacopeias. *Phytochemical Analysis*, *36*(8), 2401–2416. https://doi.org/10.1002/pca.3516